Vaccines for covid-19 patients

If you want to see all comparisons, please click here

CoronaVac vs Placebo

You will find below the forest plots for this comparison with the general characteristics and risk of bias assessment for all RCTs identified.
Of note all trials may not be included in the synthesis.

Forest plots
Trial Type Comparisons Design Participants Sample size Overall risk
of bias
Highest assessment
Full description
Intervention 1 Intervention 2
NCT04651790
Sinovac Research and Development Co., Ltd
Bueno S, medRxiv, 2021

Full text
Commentary
Commentary
Inactivated virus

CoronaVac

Placebo

RCT
Phase 3
Adult healthcare workers with no history of confirmed symptomatic SARS-CoV-2 infection who were in contact with possible or confirmed cases of COVID-19 in 8 sites in Chile. N=434
Low
Details

Full description

NCT04551547
Sinovac Life Sciences
Han B, SSRN, 2021

Full text
Commentary
Commentary
Inactivated virus

CoronaVac 1.5 mcg

Adjuvant

CoronaVac 3.0 mcg

RCT
Phase 1/2
Healthy children and adolescents aged 3-17 years with no history of SARS-CoV-2 infection in a single centre in China. N=552
Low
Details

Full description

NCT04456595
Sinovac Biotech
Palacios R, SSRN, 2021
PROFISCOV

Full text
Commentary
Inactivated virus

CoronaVac

Placebo

RCT
Phase 3
Healthcare professionals with or without previous COVID-19 infection caring for COVID-19 patients at 16 centers in Brazil. N=12408
Some concerns
Details

Full description

For risk of bias assessment, we are considering the “effect of assignment to intervention” which might not be the analysis planned and reported by investigators. Consequently, when investigators planned to assess and report the “per-protocol” effect, the risk of bias for domain 2 may be evaluated as “some concerns”. We will contact investigators to obtain the results of the intent-to-treat analysis.